Amedisys downgraded to Underperform from Neutral at RW Baird

Baird said last night's proposed 2014 Medicare Home Health reimbursement cuts is the worst possible outcome for the group. The analyst said the Health Care Facilities & Services sector has moved up in anticipation of a positive outcome and now expects Amedisys and peers to miss Q2 earnings and for Street estimates to move lower. Price target lowered to $9 from $10.